litlas
Log inCreate account

Michael A. Carducci

Active 1995–2026

212
Papers
48,143
Citations
105
h-index
206
i10-index

Citations

Citations per year for Michael A. Carducci1992: 2 citations1996: 2 citations1997: 3 citations1998: 19 citations1999: 21 citations2000: 38 citations2001: 61 citations2002: 75 citations2003: 81 citations2004: 119 citations2005: 143 citations2006: 164 citations2007: 243 citations2008: 279 citations2009: 328 citations2010: 328 citations2011: 362 citations2012: 298 citations2013: 374 citations2014: 342 citations2015: 404 citations2016: 478 citations2017: 497 citations2018: 486 citations2019: 1,554 citations2020: 1,679 citations2021: 1,765 citations2022: 1,338 citations2023: 941 citations2024: 1,481 citations2025: 611 citations2026: 19 citations1993–1995: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 5,624 citing papers, 28% of this breakdownUnited Kingdom: 1,417 citing papers, 7.1% of this breakdownChina: 1,343 citing papers, 6.7% of this breakdownGermany: 1,174 citing papers, 5.8% of this breakdownItaly: 1,056 citing papers, 5.3% of this breakdownCanada: 1,038 citing papers, 5.2% of this breakdownFrance: 813 citing papers, 4.1% of this breakdownAustralia: 710 citing papers, 3.5% of this breakdownNetherlands: 600 citing papers, 3% of this breakdownJapan: 582 citing papers, 2.9% of this breakdownSpain: 581 citing papers, 2.9% of this breakdownSwitzerland: 486 citing papers, 2.4% of this breakdown
0%28%Other 23.1%

Institutions

Fields

  • Medicine63.7%
  • Biochemistry, Genetics and Molecular Biology22.2%
  • Psychology7.4%
  • Immunology and Microbiology2.9%
  • Neuroscience0.5%
  • Materials Science0.5%
  • Other2.8%

Topics

  • Prostate Cancer Treatment and Research11.2%
  • Prostate Cancer Diagnosis and Treatment5.9%
  • Radiopharmaceutical Chemistry and Applications3.2%
  • Renal cell carcinoma treatment3.2%
  • Cancer Immunotherapy and Biomarkers3.1%
  • Psychedelics and Drug Studies2.5%
  • Other70.9%

Coauthors

All papers

Open in search
  1. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial

    Authors: Roland R. Griffiths, Matthew W. Johnson, Michael A. Carducci, Annie Umbricht, William A. Richards, Brian D. Richards, Mary P Cosimano, Margaret A. Klinedinst - Journal of Psychopharmacology 2016 cited by 2,163

  2. Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3

    Authors: Howard I. Scher, Michael J. Morris, Walter M. Stadler, Celestia S. Higano, Ethan Basch, Karim Fizazi, Emmanuel S. Antonarakis, Tomasz M. Beer, Michael A. Carducci, Kim N., Paul G. Corn, Johann S. de Bono, Robert Dreicer, Daniel J. George, Elisabeth I. Heath, Maha Hussain, Wm. Kevin Kelly, Glenn Liu, Christopher J. Logothetis, David M. Nanus, Mark N. Stein, Dana E. Rathkopf, Susan F. Slovin, Charles J. Ryan, Oliver Sartor, Eric J. Small, Matthew Raymond Smith, Cora N. Sternberg, Mary-Ellen Taplin, George Wilding, Peter S. Nelson, Lawrence H. Schwartz, Susan Halabi, Philip W. Kantoff, Andrew J. Armstrong - Journal of Clinical Oncology 2016 cited by 1,603

  3. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer

    Authors: Christopher J. Sweeney, Yu‐Hui Chen, Michael A. Carducci, Glenn Liu, David F. Jarrard, Mario A. Eisenberger, Yu-Ning Wong, Noah M. Hahn, Manish Kohli, Matthew M. Cooney, Robert Dreicer, Nicholas J. Vogelzang, Joel Picus, Daniel H. Shevrin, Maha Hussain, Jorge A. García, Robert S. DiPaola - New England Journal of Medicine 2015 cited by 2,835

  4. AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer

    Authors: Emmanuel S. Antonarakis, Changxue Lu, Hao Wang, Brandon Luber, Mari Nakazawa, Jeffrey C. Roeser, Yan Chen, Tabrez A. Mohammad, Yidong Chen, Helen Fedor, Tamara L. Lotan, Qizhi Zheng, Angelo M. De Marzo, John T. Isaacs, William B. Isaacs, Rosa Nadal, Channing J. Paller, Samuel R. Denmeade, Michael A. Carducci, Mario A. Eisenberger, Jun Luo - New England Journal of Medicine 2014 cited by 2,687

  5. Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer

    Authors: Ryan Phillips, William Y. Shi, Matthew P. Deek, Noura Radwan, Su Jin Lim, Emmanuel S. Antonarakis, Steven P. Rowe, Ashley E. Ross, Michael A. Gorin, Curtiland Deville, Stephen Greco, Hailun Wang, Samuel R. Denmeade, Channing J. Paller, Shirl Dipasquale, Theodore L. DeWeese, Daniel Y. Song, Hao Wang, Michael A. Carducci, Kenneth J. Pienta, Martin G. Pomper, Adam P. Dicker, Mario A. Eisenberger, Ash A. Alizadeh, Maximilian Diehn, Phuoc T. Tran - JAMA Oncology 2020 cited by 1,140

  6. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial

    Authors: Christos E. Kyriakopoulos, Yu‐Hui Chen, Michael A. Carducci, Glenn Liu, David F. Jarrard, Noah M. Hahn, Daniel H. Shevrin, Robert Dreicer, Maha Hussain, Mario A. Eisenberger, Manish Kohli, Elizabeth R. Plimack, Nicholas J. Vogelzang, Joel Picus, Matthew M. Cooney, Jorge A. García, Robert S. DiPaola, Christopher J. Sweeney - Journal of Clinical Oncology 2018 cited by 1,106

  7. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial

    Authors: Robert J. Motzer, Brian I. Rini, David F. McDermott, Osvaldo Arén Frontera, Hans J. Hammers, Michael A. Carducci, Pamela Salman, Bernard Escudier, Benoit Beuselinck, Asim Amin, Camillo Porta, Saby George, Victoria Neiman, Sergio Bracarda, Scott S. Tykodi, Philippe Barthélémy, Raya Leibowitz‐Amit, Elizabeth R. Plimack, Sjoukje F. Oosting, Bruce G. Redman, Bohuslav Melichar, Thomas Powles, Paul Nathan, Stéphane Oudard, David Pook, Toni K. Choueiri, Frede Donskov, Marc‐Oliver Grimm, Howard Gurney, Daniel Y.C. Heng, Christian Kollmannsberger, Michael R. Harrison, Yoshihiko Tomita, Ignacio Durán, Viktor Grünwald, M. Brent McHenry, Sabeen Mekan, Nizar M. Tannir - The Lancet Oncology 2019 cited by 780

  8. Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group

    Authors: Howard I. Scher, Susan Halabi, Ian F. Tannock, Michael J. Morris, Cora N. Sternberg, Michael A. Carducci, Mario A. Eisenberger, Celestia S. Higano, Glenn J. Bubley, Robert Dreicer, Daniel Petrylak, Philip W. Kantoff, Ethan Basch, William Kevin Kelly, William D. Figg, Eric J. Small, Tomasz M. Beer, George Wilding, Alison Martin, Maha Hussain - Journal of Clinical Oncology 2008 cited by 2,241

  9. Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long‐term follow‐up of the randomized, open‐label, phase 3 CheckMate 025 trial

    Authors: Robert J. Motzer, Bernard Escudier, Saby George, Hans J. Hammers, Sandhya Srinivas, Scott S. Tykodi, Jeffrey A. Sosman, Elizabeth R. Plimack, Giuseppe Procopio, David F. McDermott, Daniel Castellano, Toni K. Choueiri, Frede Donskov, Howard Gurney, Stéphane Oudard, Martin Eduardo Richardet, Katriina Peltola, Ajjai Alva, Michael A. Carducci, John Wagstaff, Christine Chevreau, Satoshi Fukasawa, Yoshihiko Tomita, Thomas Gauler, Christian Kollmannsberger, Fabio A.B. Schutz, James Larkin, David Cella, M. Brent McHenry, Shruti Shally Saggi, Nizar M. Tannir - Cancer 2020 cited by 337

  10. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study

    Authors: Karim Fizazi, Michael A. Carducci, Matthew R. Smith, Ronaldo Damião, Janet E. Brown, Lawrence I. Karsh, Piotr Milecki, Neal D. Shore, Michael Rader, Huei Wang, Qi Jiang, Sylvia Tadros, Roger Dansey, Carsten Goessl - The Lancet 2011 cited by 1,965

  11. Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma

    Authors: Gary R. Hudes, Michael A. Carducci, Piotr Tomczak, Janice Dutcher, Robert A. Figlin, Anil Kapoor, Elżbieta Starosławska, Jeffrey A. Sosman, David McDermott, I. Bodrogi, Zoran Kovačević, Vladimir Lesovoy, Ingo G.H. Schmidt‐Wolf, О. Л. Барбараш, Erhan Gökmen, Timothy E. O’Toole, Stephanie Lustgarten, Laurence Moore, Robert J. Motzer - New England Journal of Medicine 2007 cited by 3,647

  12. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial

    Authors: Naomi B. Haas, Judith Manola, Robert G. Uzzo, Keith T. Flaherty, Christopher G. Wood, Christopher J. Kane, Michael A.S. Jewett, Janice P. Dutcher, Michael B. Atkins, Michael Pins, George Wilding, David Cella, Lynne I. Wagner, Surena F. Matin, Timothy M. Kuzel, Wade J. Sexton, Yu-Ning Wong, Toni K. Choueiri, Роберто Пили, Igor Puzanov, Manish Kohli, Walter M. Stadler, Michael A. Carducci, Robert Coomes, Robert S. DiPaola - The Lancet 2016 cited by 638

  13. Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men With Metastatic Castration-Resistant Prostate Cancer Treated With First- and Second-Line Abiraterone and Enzalutamide

    Authors: Emmanuel S. Antonarakis, Changxue Lu, Brandon Luber, Hao Wang, Yan Chen, Yezi Zhu, John L. Silberstein, Maritza N. Taylor, Benjamin L. Maughan, Samuel R. Denmeade, Kenneth J. Pienta, Channing J. Paller, Michael A. Carducci, Mario A. Eisenberger, Jun Luo - Journal of Clinical Oncology 2017 cited by 472

  14. Germline Mutations in ATM and BRCA1/2 Distinguish Risk for Lethal and Indolent Prostate Cancer and are Associated with Early Age at Death

    Authors: Rong Na, Shusen Zheng, Misop Han, Hongjie Yu, Deke Jiang, Sameep Shah, Charles M. Ewing, Liti Zhang, Kristian Novakovic, Jacqueline Petkewicz, Kamalakar Gulukota, Donald L. Helseth, Margo Quinn, Elizabeth Humphries, Kathleen E. Wiley, Sarah D. Isaacs, Yishuo Wu, Xu Liu, Ning Zhang, Chi-Hsiung Wang, Janardan D. Khandekar, Peter J. Hulick, Daniel H. Shevrin, Kathleen A. Cooney, Zhoujun Shen, Alan W. Partin, H. Ballentine Carter, Michael A. Carducci, Mario A. Eisenberger, S. Denmeade, Michael McGuire, Patrick C. Walsh, Brian T. Helfand, Charles B. Brendler, Qiang Ding, Jianfeng Xu, William B. Isaacs - European Urology 2016 cited by 341

  15. Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies

    Authors: Gwénaëlle Gravis, Jean‐Marie Boher, Yu‐Hui Chen, Glenn Liu, Karim Fizazi, Michael A. Carducci, Stéphane Oudard, Florence Joly, David Jarrard, M. Soulié, Mario Eisenberger, Muriel Habibian, Robert Dreicer, Jorge A. García, Maha H.M. Hussain, Manish Kohli, Nicholas J. Vogelzang, Joel Picus, Robert S. DiPaola, Christopher J. Sweeney - European Urology 2018 cited by 247

  16. Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer

    Authors: Emmanuel S. Antonarakis, Changxue Lu, Brandon Luber, Hao Wang, Yan Chen, Mari Nakazawa, Rosa Nadal, Channing J. Paller, Samuel R. Denmeade, Michael A. Carducci, Mario A. Eisenberger, Jun Luo - JAMA Oncology 2015 cited by 616

  17. Phase II Trial of Neoadjuvant Systemic Chemotherapy Followed by Extirpative Surgery in Patients with High Grade Upper Tract Urothelial Carcinoma

    Authors: Vitaly Margulis, Mäneka Puligandla, Edouard J. Trabulsi, Elizabeth R. Plimack, Elizabeth R. Kessler, Surena F. Matin, Guilherme Godoy, Ajjai Alva, Noah M. Hahn, Michael A. Carducci, Jean Hoffman‐Censits, Nirmish Singla, Antony Ruggeri, Leslie Howard, John McCann, Scott E. Delacroix, Matthew Matthew, Yagnesh Oza, Jennifer Wang, Benjamin A. Gartrell, Maha Hussain, Marc Matrana, Sam Benjamin, Guru Sonpavde, Elaine T. Lam, Brandon Bernard, Yousef Zakharia, Sarah E. Taylor, Matthew I. Milowsky, Sofia Ghani, Sindhu Singh, Kevin M. Kane, Yull Arriaga, Amee Morgans, David D. Chism - The Journal of Urology 2019 cited by 133

  18. A phase I study of muscadine grape skin extract in men with biochemically recurrent prostate cancer: Safety, tolerability, and dose determination

    Authors: Channing J. Paller, Michelle A. Rudek, Xian Zhou, William D. Wagner, Tamaro Hudson, Nicole M. Anders, Hans J. Hammers, Donna Dowling, Serina King, Emmanuel S. Antonarakis, Charles G. Drake, Mario A. Eisenberger, Samuel R. Denmeade, Gary L. Rosner, Michael A. Carducci - The Prostate 2015 cited by 125

  19. Engineering a Prostate-Specific Membrane Antigen–Activated Tumor Endothelial Cell Prodrug for Cancer Therapy

    Authors: Samuel R. Denmeade, Annastasiah Mhaka, Dina Rosen, W. Nathaniel Brennen, Susan L. Dalrymple, Ingrid Dach, Claus Olesen, Bora Gürel, Angelo M. De Marzo, George Wilding, Michael A. Carducci, Craig A. Dionne, Jesper V. Møller, Poul Nissen, S. Brøgger Christensen, John T. Isaacs - Science Translational Medicine 2012 cited by 217

  20. TRANSFORMER: A Randomized Phase II Study Comparing Bipolar Androgen Therapy Versus Enzalutamide in Asymptomatic Men With Castration-Resistant Metastatic Prostate Cancer

    Authors: Samuel R. Denmeade, Hao Wang, Neeraj Agarwal, David C. Smith, Michael T. Schweizer, Mark N. Stein, Vasileios J. Assikis, Przemyslaw Twardowski, Thomas W. Flaig, Russell Z. Szmulewitz, Jeffrey M. Holzbeierlein, Ralph J. Hauke, Guru Sonpavde, Jorge A. García, Arif Hussain, Oliver Sartor, Shifeng Mao, Harry Cao, Wei Fu, Ting Wang, Rehab Abdallah, Su Jin Lim, Vanessa Bolejack, Channing J. Paller, Michael A. Carducci, Mark C. Markowski, Mario A. Eisenberger, Emmanuel S. Antonarakis - Journal of Clinical Oncology 2021 cited by 137

  21. Immune-related adverse events with immune checkpoint inhibitors affecting the skeleton: a seminal case series

    Authors: Kendall F. Moseley, Jarushka Naidoo, Clifton O. Bingham, Michael A. Carducci, Patrick M. Forde, Geoffrey T. Gibney, Evan J. Lipson, Ami A. Shah, William H. Sharfman, Laura C. Cappelli - Journal for ImmunoTherapy of Cancer 2018 cited by 99

  22. Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer

    Authors: Wennuan Liu, Sari Laitinen, Sofia Khan, Mauno Vihinen, Jeanne Kowalski, Guoqiang Yu, Li Chen, Charles M. Ewing, Mario A. Eisenberger, Michael A. Carducci, William G. Nelson, Srinivasan Yegnasubramanian, Jun Luo, Yue Wang, Jianfeng Xu, William B. Isaacs, Tapio Visakorpi, G. Steven Bova - Nature Medicine 2009 cited by 660

  23. Predicting Renal Cancer Recurrence: Defining Limitations of Existing Prognostic Models With Prospective Trial-Based Validation

    Authors: Andres Correa, Opeyemi A. Jegede, Naomi B. Haas, Keith T. Flaherty, Michael R. Pins, Edward M. Messing, Judith Manola, Christopher G. Wood, Christopher J. Kane, Michael A.S. Jewett, Janice P. Dutcher, Robert S. DiPaola, Michael A. Carducci, Robert G. Uzzo - Journal of Clinical Oncology 2019 cited by 153

  24. Nivolumab plus ipilimumab, with or without enzalutamide, in AR‐V7‐expressing metastatic castration‐resistant prostate cancer: A phase‐2 nonrandomized clinical trial

    Authors: Eugene Shenderov, Karim Boudadi, Wei Fu, Hao Wang, Rana Sullivan, Alice Jordan, Donna Dowling, Rana Harb, Joseph D. Schonhoft, Adam Jendrisak, Michael A. Carducci, Mario A. Eisenberger, James R. Eshleman, Jun Luo, Charles G. Drake, Drew M. Pardoll, Emmanuel S. Antonarakis - The Prostate 2021 cited by 69